Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

References

• Luessi F, Siffrin V, Zipp F. Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev Neurother 2012;12:1061-76; quiz 77
   PubMed Web of Science ®Google Scholar
• Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 2011;17(Suppl5):S139-S45
   Google Scholar
• Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012;5:205-20
   PubMed Web of Science ®Google Scholar
• Remington G, Rodriguez Y, Logan D, et al. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care 2013;15:36-45
   PubMedGoogle Scholar
• Gasperini C, Ruggieri S. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther 2012;6:175-86
   PubMed Web of Science ®Google Scholar
• Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol 2011;10:1026-34
   PubMed Web of Science ®Google Scholar
• English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther 2015;37:691-715
   PubMed Web of Science ®Google Scholar
• Sharma S, Mathur AG, Pradhan S, et al. Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother 2011;2:49-51
   PubMedGoogle Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Bomprezzi R. Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Ther Adv Neurol Disord 2015;8:20-30
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing–remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol 2015;2:103-18
   PubMed Web of Science ®Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol 2014;261:1794-802
   PubMed Web of Science ®Google Scholar
• Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 2015;84:1145-52
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf 2012;21(Suppl2):130-7
   Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin 2011;27:1263-71
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Swallow E, et al. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig 2011;31:665-74
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28:935-45
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(Pt 5):871-82
   PubMed Web of Science ®Google Scholar
• EuroQol Group – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing–remitting multiple sclerosis. Adv Ther 2014;31:1134-54
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27
   PubMed Web of Science ®Google Scholar
• Judkins DR, Morganstein D, Zador P, et al. Variable selection and raking in propensity scoring. Stat Med 2007;26:1022-33
   PubMed Web of Science ®Google Scholar
• Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011;173:1404-13
   PubMed Web of Science ®Google Scholar
• Millimet DL, Tchernis R. On the specification of propensity scores, with applications to the analysis of trade policies. J Bus Econ Stat 2009;27:397-415
   Web of Science ®Google Scholar
• Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987;82:387-94
   Web of Science ®Google Scholar